Tumour Working Group and Cancer Clinical Leads Forum

1. Tumour Working Group and Cancer Clinical Leads Forum Monday 3rd December 2012

2. Welcome and Introduction Prof Arnie Purushotham, LCA Joint Interim Clinical Director • Welcome • Outline the purpose of the event • Housekeeping

3. Clinical Leadership within the LCA • Appointment process for Clinical Director and Associate Clinical Director – interviews 11th December 2012 • Appointment process for Pathway Group Chairs • 12 Pathway Groups (tumour specific only) • Covering letter, advert, job description and job specification emailed to CEOs, Medical Directors, Cancer Clinical Leads and Cancer Nurse Leads • Applicants to send a covering letter and CV emailed to Claire Dowling LCA Programme Director • Closing date for applications by 12 noon 24th December 2012 • Interviews to be held week commencing 21st & 28th January 2013 • Interview panel to include Clinical Director, Associate Clinical Director, Programme Director and Cancer Unit representative from the Interim Clinical Board • Questions?

4. LCA Progress to date • Establishment of the Members Board and appointment of the Independent Chairs for the Members Board and Clinical Board • Progress against the Clinical Plan • 1st Wave responses to the MoC • Pan London agreement on best practice commissioning pathways in colorectal, lung, brain/CNS and breast • LCA wide best practice clinical guidelines in Breast, OG, Lung, AOS, Survivorship & Palliative Care either agreed or in final version ready for implementation January 2013 • Leading voice in pan London informatics agenda driving progress in completeness of staging, SACT, TCR, agreement of commissioning metrics and development of LCA scorecards • Macmillan project progress on Patient Experience, Patient Information, Chemotherapy closer to Home & Survivorship

5. LCA Progress to date • Emergency presentation audit underway • Improved engagement and communication including the final stages of development of the LCA website, stakeholder engagement forums across the pathway groups, AOS simulation courses • Development of the User Partnership agenda across London • Development of new systems and processes for Peer Review and the wider quality agenda

6. But there is much more to do…….. • Appointment of Clinical Director & Associate Clinical Director • Establishment of remaining pathway groups and appointment of tumour-specific Pathway Group Chairs • Delivery of the MoC recommendations in all pathway groups • Promoting prevention and early detection of cancer by supporting GPs and public health messages • Development of the early diagnosis agenda & LCA endoscopy • Delivery of significant improvement in patient experience and patient information across all pathway groups • Development and delivery of the LCA Medicines and Chemotherapy agenda including chemotherapy closer to home • Mental Health and Psychological medicine • LCA Cancer research and training agenda • Engagement with the CCGs • Development and implementation of a communications strategy • Improved collaborative working across south and west London

7. Commissioning and strategic priorities Dr Kate Haire, LCA Clinical Commissioning

8. Cancer Commissioning Teams and London Cancer Programme governance structure Operating structure from 1 April 2013

9. Commissioning of cancer services Model of Care for Cancer Services (NHS London 2010) London Cancer Programme: Strategic Themes • Improving Early Detection • Delivering care closer to home • Consistency of care • Consolidation of services • Delivering productivity and efficiency

10. LCA Strategic Priorities • Work with London Cancer Programmes to develop 3 year plan for delivery of Model of Care • LCA Clinical Service Plan • LCA Strategic Priorities: Pathway specific and cross cutting priorities • Key issues • Flexibility to take account of emerging priorities • Work of London Cancer Integrated Cancer System • Commissioning arrangements from 2013 • Resources • Wider political context

11. Preparation for Peer Review Mr Nick Hyde, Cancer Director St George’s Healthcare NHS Trust

12. LCA Peer Review Progress • Transition of the SE, SW & NW Cancer Network provider functions to the LCA • Mapping of current peer review measures across to LCA structures and processes • LCA Peer Review Transition Plan in final draft • Network Board measures transfer to Joint Development Group due to composition and function of JDG • Existing TWG arrangements remain in place with accountability to the Pathway groups and Clinical Board • Approach maintains oversight & guidance to MDTs until 31st March; assurance to peer review

14. LCA Peer Review Progress • From April 1st TWG meetings will be replaced with Pathway Group led quarterly tumour specific clinical forums – ensures compliance to 1c measures • These quarterly forums will ensure clinical governance is at the heart of the LCA and will facilitate - clinical audit/clinical effectiveness - patient safety/ patient experience - clinical research - training and education - user involvement and service improvement - vertical communication

15. LCA Peer Review 2013/14 • Collaborative partnership working with NCAT • Development of a “Skinny” Peer Review– essential components to assure quality standards, systems and processes across the LCA • Development of a Pathway Group Constitution to include: - operational policy - an annual report - work plan • Any Questions?

16. NCAT Plans and Legacy Ms Ruth Bridgeman, National Programme Director, Peer Review

17. New Improvement Body (nIB) • Will bring together several legacy organisations • NHS Institute • NHS Improvement • National Cancer Action Team • End of Life Care Programme • NHS Diabetes and Kidney • National Technology Adoption Centre • Work programme will be based around priorities identified by the 5 Domain Directors • Julian Hartley appointed as Interim Managing Director

18. Business Continuity • Some programmes of work will transfer to the nIB • Some programmes will close because the work is completed • Some programmes will need to continue and a suitable host will need to be found for it i.e. National Cancer Peer Review Programme • Some programmes will be discontinued • We need to capture the learning from all the work we have done. • We need to ensure that the learning is passed on to successor organisations

19. Transition Delivery Partner (TDP) • Will be established to continue some of the work of existing programmes and to commence delivery on new areas of work • TDP will exist for a period up to one year from April 2013 to March 2014 • Work programme will emerge from the nIB Business Plan • It is proposed that the National Cancer Peer Review Programme will initially form part of the TDP

20. Change Presentation title and date in Footer dd.mm.yyyy Developing the future Peer Review Programme • Greater focus on Outcomes • Using Service Profiles • Limited data available currently • Fewer Measures • Some process measures will be required • Minimising the evidence required • Operational Policy • Annual Report • Work Programme • Greater Transparency of the reports • My Cancer Treatment

21. Change Presentation title and date in Footer dd.mm.yyyy

22. Change Presentation title and date in Footer dd.mm.yyyy

23. Click here to view the full report

24. Peer Review – break out session Mr Nick Hyde, Cancer Director St George’s Healthcare NHS Trust

25. Break out session – 30 mins brainstorm 15 mins feedback session What are the essential components of Peer Review? • Innovative ways of working • What’s new that can be applied to Peer Review in 2013 • Essential documentation • Essential structures, systems and processes • Essential feedback mechanisms • Assurance across 17 provider organisations

26. Closing Remarks Mr Justin Vale, Joint Interim Clinical Director